Moderna plans to test a booster shot of its Covid-19 vaccine a year after the first two-dose vaccination, as the duration of protection against the brand new vaccines is still unclear.
According to a company presentation this week, the biotech company plans to start the trial in July. According to an email shared by one of these people, clinical trial sites have already started contacting participants in previous trials.
“From what we’ve seen so far, we’re assuming the vaccination will take at least a year,” said Dr. Tal Zaks, Chief Medical Officer of Moderna, spoke to investors and analysts at the JPMorgan Healthcare Conference on Monday. “To the extent that you need a booster shot, we make a data-based recommendation, and for that we need to pull the data.”
The first participants in Moderna’s human clinical trials received their recordings in mid-March. a second was given four weeks later. Because multiple doses of the vaccine were tested in previous studies, those with doses lower than what was ultimately approved – 100 micrograms – would receive boosters earlier, while those with 100 micrograms or more would receive their booster at the end of the year. Mail to the participants.
The booster that is now planned is the same version of the vaccine that is on the market, but Stephane Bancel, CEO of Moderna, said it might be necessary to adapt the vaccine in the coming years to cover new variants.
“I think this is going to be a market like the flu,” he told CNBC. Moderna also recently started a seasonal flu vaccination program.
The booster study for Moderna’s Covid-19 vaccine will assess both safety and the immune response that an additional shot generates a year later, Bancel said at the conference this week.